6,7-Diethoxy-1,2-diphenyl-1,4-dihydroisoquinolin-3-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 6,7-Diethoxy-1,2-diphenyl-1,4-dihydroisoquinolin-3-one
• 化学式: C₂₅H₂₅NO₃
• 分子量: 387.5
• InChiKey: WVWOWZIVUDVZRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof
  申请人：Sanford Burnham Prebys Medical Discovery Institute

  公开号：US11028061B2

  公开（公告）日：2021-06-08

  Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject. Also disclosed are method for treating one or more Myc-driven cancers, including neuroblastoma, lung squamous cell carcinoma/lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, acute myeloid leukemia, and breast invasive carcinoma.

  用于降低受试者血糖和/或增加胰岛素信号传导的制剂和方法已经研制成功。这些制剂包括SBI-477和基于SBI-477的化合物，即SBI-477类似物（统称为SBI-477化合物）和/或蒙多家族抑制剂，与未施用该组合物的对照组相比，其有效量可抑制细胞内脂质积累和/或增加细胞葡萄糖摄取。还公开了减少有需要的受试者细胞内脂质积累和/或增加葡萄糖摄取的方法。该方法包括向受试者施用有效量的 SBI-477 化合物和/或蒙多家族抑制剂，以减少细胞内脂质积累和/或增加受试者的葡萄糖摄取。还公开了治疗一种或多种Myc驱动的癌症的方法，包括神经母细胞瘤、肺鳞癌/肺腺癌、肝肝细胞癌、结肠腺癌、急性髓性白血病和乳腺浸润性癌。
• MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF
  申请人：Sanford Burnham Prebys Medical Discovery Institute

  公开号：US20180222874A1

  公开（公告）日：2018-08-09

  Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject. Also disclosed are method for treating one or more Myc-driven cancers, including neuroblastoma, lung squamous cell carcinoma/lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, acute myeloid leukemia, and breast invasive carcinoma.